No Data
No Data
Both Retail Investors Who Control a Good Portion of Yantai Dongcheng Pharmaceutical Group Co.,Ltd. (SZSE:002675) Along With Institutions Must Be Dismayed After Last Week's 3.3% Decrease
Key Insights The considerable ownership by retail investors in Yantai Dongcheng Pharmaceutical GroupLtd indicates that they collectively have a greater say in management and business strategy A tota
Dongcheng Biochemicals' Unit Gets Nod to Trial Pancreatic Cancer Drug
Yantai Dongcheng Biochemicals' (SHE:002675) unit, Yantai Lannacheng Biotechnology, will conduct clinical trials on the 177LuLNC1010 injection after receiving approval from China's National Medical Pro
Dongcheng Pharmaceutical (002675.SZ): Clinical trial application approved for ¹ Lu-LNC1010 injection
Dongcheng Pharmaceutical (002675.SZ) issued an announcement that the company's holding subsidiary, Yantai Lannacheng Biotechnology Co., Ltd. (...
Ping An Securities: The terminal market resumes growth and selects varieties based on space and pattern
Ping An Securities released a research report saying that judging from changes in the scale and pattern of terminal drug use, the industry ushered in restorative growth in the post-pandemic era. Innovative drugs and varieties with high barriers and good patterns are growing faster than the overall growth rate.
Hebei Andike, a subsidiary of Dongcheng Pharmaceutical (002675.SZ), was recognized as a specialized, special and new small and medium-sized enterprise in Hebei Province
Dongcheng Pharmaceutical (002675.SZ) announced that the company's subsidiary, Hebei Andikezheng Electronics Technology Co., Ltd. (abbreviation...
US FDA Grants Clinical Trial Approval for Dongcheng Biochemicals' Injection
The US FDA granted Yantai Dongcheng Biochemicals' (SHE:002675) clinical trial application for its 18F-LNC1007 injection targeting tumors, according to a Tuesday filing with the Shenzhen bourse. The in
No Data